Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (11969)	5/23/2013 9:35:43 AM
From: LT2011	Read Replies (1) \| Respond to of 13111

Once again thank you. In your opinion the dosing schedule is the most critical portion? What would be an acceptable dosing schedule for PVCT hope for and what dosing schedule would be the "kiss of death"? Since we do not know the finalized PV-10 dosing schedule, I can not guestimate the likely success of a PIII trial designed with a head to head comparison of IL PV-10 to a systemic Tx in stage IIIb and IIIc patients using a primary outcome of progression free survival. My recent reading of mouse data that includes limited drug comparisons is not encouraging, but I could also see a 'rolling enrollment' strategy that might mitigate some of the dosing concerns (although I think they would need more than the proposed 180 patients for that)